Crescent Biopharma, Inc.CBIONASDAQ
Loading
CBIO Revenue Growth (YoY Quarterly)•+0.00%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+0.00%
+0.0pp
+39799.42%
+39799.4pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+61.49%
+20.6pp
+61.49%
+0.3pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +170.43% | +0.00% | +0.00% | +0.00% | +39799.42% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.14% | +0.10% | +19.62% | +40.89% | +61.49% |
| Weighted Average Shares Diluted Growth | +0.14% | +0.10% | +19.62% | +61.24% | +61.49% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -190.32% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -193.30% | +0.00% |
| Receivables Growth | -22.32% | -100.00% | -100.00% | -100.00% | +13079.09% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -75.52% | -82.48% | +544.72% | +780.80% | +2066.47% |
| Book Value per Share Growth | -86.19% | -88.34% | +480.23% | +627.74% | +2265.84% |
| Debt Growth | -91.73% | -100.00% | +585.64% | +1069.25% | +2359.46% |
| R&D Expense Growth | -95.59% | -99.75% | +92.20% | +1086.17% | +40646.70% |
| SG&A Expenses Growth | +17.83% | -53.16% | +119.77% | +38.24% | +67.66% |
1 / 4